Dose Escalation Study of OMP-54F28 in Combination With Sorafenib in Patients With Hepatocellular Cancer
A Phase 1b Dose Escalation Study of OMP-54F28 in Combination With Sorafenib in Patients With Hepatocellular Cancer
Sponsor: OncoMed Pharmaceuticals, Inc.
This PHASE1 trial investigates Hepatocellular Cancer and Liver Cancer and is currently completed. OncoMed Pharmaceuticals, Inc. leads this study, which shows 8 recorded versions since 2014 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Sep 2020 — Jan 2021 [monthly]
Completed PHASE1
-
Jun 2018 — Sep 2020 [monthly]
Completed PHASE1
▶ Show 3 earlier versions
-
Sep 2017 — Jun 2018 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Feb 2017 — Sep 2017 [monthly]
Active Not Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE1
First recorded
Jan 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- OncoMed Pharmaceuticals, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .